Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, the company's President and CEO, will engage in a fireside chat during the conference, which is scheduled for February 5-6, 2025, in New York.
The presentation is set for Wednesday, February 5, 2025, at 2:00 p.m. ET. Interested parties can access the live audio webcast through the Investors section of Adicet Bio's website. A replay of the presentation will remain available for 30 days following the event.
Adicet Bio (Nasdaq: ACET), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di terapie cellulari gamma delta T allogeniche, ha annunciato la sua partecipazione alla prossima Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, Presidente e CEO dell'azienda, parteciperà a una conversazione informale durante la conferenza, che si terrà il 5-6 febbraio 2025, a New York.
La presentazione è prevista per mercoledì 5 febbraio 2025, alle 14:00 ET. Le parti interessate possono accedere alla diretta audio webcast attraverso la sezione Investor del sito web di Adicet Bio. Una registrazione della presentazione sarà disponibile per 30 giorni dopo l'evento.
Adicet Bio (Nasdaq: ACET), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares gamma delta T alogénicas, ha anunciado su participación en la próxima Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, Presidente y CEO de la compañía, participará en una charla informal durante la conferencia, programada para el 5 y 6 de febrero de 2025, en Nueva York.
La presentación está programada para el miércoles 5 de febrero de 2025, a las 2:00 p.m. ET. Las partes interesadas pueden acceder a la transmisión de audio en vivo a través de la sección de inversionistas del sitio web de Adicet Bio. Una repetición de la presentación estará disponible durante 30 días después del evento.
Adicet Bio (Nasdaq: ACET)는 동종 감마 델타 T 세포 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, 구겐하임 증권 SMID 캡 생명공학 회의에 참여한다고 발표하였습니다. 회사의 사장 겸 CEO인 Chen Schor는 2025년 2월 5-6일 뉴욕에서 열리는 회의 중에 편안한 대화에 참여할 예정입니다.
발표는 2025년 2월 5일 수요일 오후 2시 ET로 예정되어 있습니다. 관심 있는 당사자는 Adicet Bio 웹사이트의 투자자 섹션을 통해 라이브 오디오 웨비나에 접속할 수 있습니다. 발표의 녹화는 이벤트 이후 30일 동안 이용 가능할 것입니다.
Adicet Bio (Nasdaq: ACET), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires gamma delta T allogéniques, a annoncé sa participation à la prochaine Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, Président et PDG de l'entreprise, participera à une discussion informelle pendant la conférence, qui se tiendra les 5 et 6 février 2025 à New York.
La présentation est prévue pour le mercredi 5 février 2025 à 14h00 ET. Les parties intéressées peuvent accéder à la diffusion audio en direct via la section investisseurs du site Web d'Adicet Bio. Un enregistrement de la présentation sera disponible pendant 30 jours après l'événement.
Adicet Bio (Nasdaq: ACET), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen Gamma-Delta-T-Zelltherapien konzentriert, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference bekannt gegeben. Chen Schor, President und CEO des Unternehmens, wird während der Konferenz, die für den 5.-6. Februar 2025 in New York geplant ist, in einem informellen Gespräch teilnehmen.
Die Präsentation ist für Mittwoch, den 5. Februar 2025, um 14:00 Uhr ET angesetzt. Interessierte können über den Bereich Investoren auf der Website von Adicet Bio auf den Live-Audio-Webcast zugreifen. Eine Wiederholung der Präsentation wird für 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Details of the event are as follows:
Date: Wednesday, February 5, 2025
Time: 2:00 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129760119/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
When is Adicet Bio (ACET) presenting at the Guggenheim Securities SMID Cap Biotech Conference 2025?
How can investors watch Adicet Bio's (ACET) Guggenheim Securities conference presentation?
What type of therapies is Adicet Bio (ACET) developing?
Who will represent Adicet Bio (ACET) at the Guggenheim Securities conference?
